Effective Neutralizing Antibody Produced in Mice Directly Immunized with Integrated Pichia pastoris Expressing HPV16L1 Protein

Viral Immunology
Zhen XvWenshu Li

Abstract

The human papillomavirus (HPV) vaccine has not been widely used in developing countries because of its high cost and multiple subtype restrictions. The present study aimed to develop an economical, convenient, and effective vaccine to produce neutralizing antibodies. Using late protein 1 (L1) from the HPV16 subtype as the target antigen (HPV16L1) and Pichia pastoris as the antigen release system, integrated P. pastoris expressing HPV16L1 (named yeast-HPV16L1) was prepared and vaccinated directly into mice by subcutaneous multipoint injection. After immunization was performed thrice, high titers (greater than 1:40,960) of specific anti-HPV16L1 antibodies were obtained in immune serum and were observed to continuously rise over time. The indirect hemagglutination test and indirect hemagglutination inhibition test were used to detect neutralizing antibody activity in vitro, and the results demonstrated the hemagglutination ability of the immune serum and the reduction in or loss of the hemagglutination ability if preneutralized antigen was added to the immune serum. The protection conferred by immune serum to tumor-bearing mice at the early stages was confirmed, but the neutralizing activity disappeared when the tumor reached a si...Continue Reading

References

Nov 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·A OzinskyA Aderem
Jan 5, 2002·Cellular and Molecular Life Sciences : CMLS·G Dell, K Gaston
May 15, 2007·The New England Journal of Medicine·Suzanne M GarlandUNKNOWN Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators
Sep 12, 2007·Experimental Dermatology·Helge RiemannMayumi Fujita
Jul 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elizabeth K WansleyJames W Hodge
Oct 19, 2010·The Lancet Oncology·Silvia de SanjoseUNKNOWN Retrospective International Survey and HPV Time Trends Study Group
Nov 6, 2012·Journal of Microbiology and Biotechnology·Woo-Taeg KwonHyun Kang
Jun 12, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Salvatore VaccarellaFreddie Bray
Apr 20, 2014·Applied Microbiology and Biotechnology·Mudassar AhmadHelmut Schwab
Sep 11, 2014·Microbial Cell Factories·Claudia RuthBrigitte Gasser
Mar 20, 2015·PloS One·Mariana Aprigio Assis-MarquesPaulo Sergio Rodrigues Coelho
Jul 1, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Beatriz SerranoLaia Alemany
Jan 26, 2016·CA: a Cancer Journal for Clinicians·Wanqing ChenJie He
Jan 23, 2019·FEMS Yeast Research·Ravinder Kumar, Piyush Kumar

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Datasets Mentioned

BETA
MG516827
AXS67903

Methods Mentioned

BETA
PCR
electrophoresis
enzyme-linked immunosorbent assay
ELISA
dot immunobinding assay
glycosylation

Software Mentioned

JCat
SPSS

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.